Your browser is no longer supported. Please, upgrade your browser.
Amarin Corporation plc
Index- P/E454.55 EPS (ttm)0.01 Insider Own1.20% Shs Outstand395.90M Perf Week-3.10%
Market Cap1.98B Forward P/E- EPS next Y-0.04 Insider Trans-2.16% Shs Float380.97M Perf Month-8.09%
Income4.30M PEG11.68 EPS next Q-0.04 Inst Own33.90% Short Float4.54% Perf Quarter26.90%
Sales620.40M P/S3.19 EPS this Y28.70% Inst Trans0.45% Short Ratio5.40 Perf Half Y-3.47%
Book/sh1.63 P/B3.07 EPS next Y-100.00% ROA0.40% Target Price10.75 Perf Year-0.40%
Cash/sh1.29 P/C3.89 EPS next 5Y38.90% ROE0.70% 52W Range3.84 - 9.25 Perf YTD2.25%
Dividend- P/FCF- EPS past 5Y43.60% ROI-3.30% 52W High-45.95% Beta2.17
Dividend %- Quick Ratio2.00 Sales past 5Y49.70% Gross Margin79.30% 52W Low30.38% ATR0.13
Employees1000 Current Ratio2.70 Sales Q/Q14.20% Oper. Margin1.20% RSI (14)42.51 Volatility2.01% 2.71%
OptionableYes Debt/Eq0.00 EPS Q/Q75.80% Profit Margin0.70% Rel Volume0.62 Prev Close5.01
ShortableYes LT Debt/Eq0.00 EarningsNov 03 BMO Payout0.00% Avg Volume3.20M Price5.00
Recom2.30 SMA20-1.99% SMA50-5.27% SMA200-8.62% Volume1,984,285 Change-0.20%
May-12-21Downgrade Goldman Neutral → Sell $6 → $5
Sep-29-20Resumed JP Morgan Neutral
Aug-26-20Initiated Piper Sandler Overweight $21
May-05-20Initiated Northland Capital Outperform $15
Mar-31-20Upgrade Oppenheimer Underperform → Perform
Mar-31-20Downgrade Jefferies Buy → Hold $30 → $4
Mar-31-20Downgrade Goldman Buy → Neutral
Mar-13-20Upgrade Goldman Neutral → Buy $28
Mar-02-20Initiated Cowen Outperform $23
Feb-18-20Upgrade Citigroup Neutral → Buy $27 → $24
Jan-06-20Initiated JP Morgan Neutral $22
Dec-16-19Downgrade Stifel Buy → Hold
Nov-20-19Initiated Oppenheimer Underperform $7
Nov-18-19Downgrade Citigroup Buy → Neutral
Nov-15-19Reiterated SVB Leerink Outperform $26 → $29
Oct-31-19Initiated Aegis Capital Buy $23
Oct-15-19Initiated Goldman Neutral $17
Aug-14-19Initiated SVB Leerink Outperform $26
Jul-09-19Reiterated Jefferies Buy $30
Jun-17-19Initiated ROTH Capital Buy $31
Oct-24-21 09:00AM  
Oct-23-21 12:15PM  
Oct-22-21 08:00PM  
Oct-20-21 07:05AM  
Oct-11-21 12:00PM  
Sep-27-21 02:01PM  
Sep-24-21 05:40AM  
Sep-22-21 09:15AM  
Sep-13-21 07:00AM  
Sep-08-21 06:06AM  
Aug-31-21 07:00AM  
Aug-23-21 03:15AM  
Aug-16-21 07:00AM  
Aug-07-21 03:29AM  
Aug-06-21 10:12AM  
Aug-05-21 02:34PM  
Aug-03-21 09:59AM  
Jul-19-21 12:50PM  
Jul-15-21 06:35AM  
Jun-22-21 06:13PM  
Jun-21-21 11:30AM  
Jun-02-21 04:30PM  
May-18-21 06:19PM  
May-17-21 04:05PM  
May-15-21 08:00AM  
May-12-21 11:03AM  
May-04-21 07:00AM  
Apr-29-21 08:01PM  
Apr-26-21 09:49AM  
Apr-22-21 10:53AM  
Apr-21-21 01:18PM  
Apr-20-21 06:05AM  
Apr-17-21 09:50AM  
Apr-15-21 10:45AM  
Apr-13-21 03:05PM  
Apr-12-21 04:30PM  
Apr-10-21 06:40AM  
Apr-09-21 07:33AM  
Apr-06-21 06:05AM  
Apr-01-21 06:22AM  
Mar-30-21 05:22PM  
Mar-29-21 07:28AM  
Mar-17-21 11:30AM  
Mar-09-21 11:41PM  
Mar-01-21 08:00AM  
Feb-26-21 09:47AM  
Feb-25-21 11:21AM  
Feb-18-21 06:05AM  
Feb-17-21 08:05AM  
Feb-09-21 07:00PM  
Feb-07-21 11:27PM  
Feb-01-21 06:25PM  
Jan-29-21 12:52PM  
Jan-26-21 08:07AM  
Jan-25-21 07:35PM  
Jan-24-21 06:08AM  
Jan-22-21 07:22AM  
Jan-21-21 04:30PM  
Jan-09-21 01:36AM  
Jan-07-21 06:05AM  
Jan-05-21 09:32AM  
Jan-04-21 06:05AM  
Dec-31-20 08:46AM  
Dec-21-20 09:41AM  
Dec-14-20 05:00AM  
Dec-12-20 09:30PM  
Dec-11-20 10:01AM  
Dec-07-20 07:00AM  
Dec-06-20 11:41PM  
Dec-01-20 08:08AM  
Nov-30-20 07:55PM  
Nov-24-20 06:05AM  
Nov-22-20 06:28AM  
Nov-20-20 10:20AM  
Nov-19-20 06:30PM  
Nov-18-20 07:00AM  
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kalb Michael WayneSVP and CFOAug 12Option Exercise2.35120,000281,800325,010Aug 13 08:04 PM
Kalb Michael WayneSVP and CFOAug 12Sale5.25120,000630,240205,010Aug 13 08:04 PM
STACK DAVID MDirectorJun 04Buy4.5410,00045,35040,000Jun 07 09:53 PM
STACK DAVID MDirectorJun 03Buy4.625,00023,11530,000Jun 07 09:53 PM
Ketchum Steven BChief Scientific OfficerFeb 01Option Exercise2.53192,358485,882600,724Feb 03 08:02 PM
Ketchum Steven BChief Scientific OfficerFeb 01Sale8.06217,7281,754,134382,996Feb 03 08:02 PM
Ketchum Steven BChief Scientific OfficerJan 27Option Exercise2.75278,237764,566809,741Jan 29 08:03 PM
Ketchum Steven BChief Scientific OfficerJan 27Sale8.01421,6293,378,131388,112Jan 29 08:03 PM
STACK DAVID MDirectorNov 30Buy4.8625,000121,51725,000Dec 02 08:05 PM
THERO JOHN FPresident and CEONov 11Sale4.07413,5651,681,1832,739,000Nov 12 08:01 PM
THERO JOHN FPresident and CEONov 10Option Exercise3.40615,2612,091,8873,306,405Nov 12 08:01 PM
THERO JOHN FPresident and CEONov 10Sale4.13153,840635,9753,152,565Nov 12 08:01 PM
THERO JOHN FPresident and CEONov 09Option Exercise3.40134,739458,1132,691,144Nov 12 08:01 PM